Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Prilosec OTC Packaging Change Gives Consumers Easier Access

This article was originally published in The Tan Sheet

Executive Summary

Packaging changes for Procter & Gamble's Prilosec OTC proton-pump inhibitor are intended to make it easier to remove the product, according to brand executive Matt Champion

You may also be interested in...



Sanofi Changes Allegra-D Blister Packs Based On Facebook Comments

After consumers posted on the brand’s Facebook page that they struggled with the foil blister packs, the firm responded to the problem promptly by changing the packaging and directions. The two-way interaction of social media allowed Sanofi to gather consumer information and keep users posted on changes.

Sanofi Changes Allegra-D Blister Packs Based On Facebook Comments

After consumers posted on the brand’s Facebook page that they struggled with the foil blister packs, the firm responded to the problem promptly by changing the packaging and directions. The two-way interaction of social media allowed Sanofi to gather consumer information and keep users posted on changes.

Facebook Posts Point Sanofi To Change Allegra-D Foil Packaging

Sanofi changed the packaging design and the directions for removing the tablets after consumers stated on the brand’s Facebook page that they struggled with the foil blister packs. Chattem learned about and responded to the problem promptly through the two-way interaction that social media allows.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS101700

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel